# US 9,556,236 B1 · Compositions and methods for treating respiratory syncytial virus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,556,236 B1
- Document ID: US9556236B1
- Status: Granted
- Kind: B1
- Application number: 14/093,107
- Filed: 2013-11-29
- Granted: 2017-01-31
- Earliest claimed: 2012-11-29
- Assignees: University of South Florida
- Applicants: Shyam S. Mohapatra; Nancy Lucrecia Goicochea; Suraj Dixit; Julio Garay
- Inventors: Shyam S. Mohapatra; Nancy Lucrecia Goicochea; Suraj Dixit; Julio Garay
- Web page: https://patentgrep.com/patent/US9556236B1

## CPC

- C07K 14/005: from viruses
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 38/162: {from virus}
- C12N 2760/18033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Briefly described, embodiments of the present disclosure relate to isolated polypeptides useful for treatment of respiratory syncytial virus, and to methods and compositions for treating respiratory syncytial virus.

## Claims

### Claim 1

An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:10.

### Claim 2 (depends on 1)

The isolated polypeptide of claim 1, wherein the amino acid sequence is SEQ ID NO:2.

### Claim 3 (depends on 1)

The isolated polypeptide of claim 1, wherein the amino acid sequence is SEQ ID NO:7.

### Claim 4 (depends on 1)

The isolated polypeptide of claim 1, wherein the isolated polypeptide consists essentially of: an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:10.

### Claim 5

A composition comprising a micelle having a lipid layer and a core, wherein the core comprises a first polypeptide, and wherein the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:10.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the amino acid sequence is SEQ ID NO:7 or SEQ ID NO:2.

### Claim 7 (depends on 5)

The composition of claim 5, wherein the first polypeptide consists essentially of an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:10.

### Claim 8 (depends on 5)

The composition of claim 5, wherein the lipid layer comprises amine-PEG-PE.

### Claim 9 (depends on 5)

The composition of claim 5, wherein the lipid layer comprises amine-PEG-PE, methoxy-PEG-PE, and DSPC, and wherein the first polypeptide comprises SEQ ID NO:7.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the micelle is prepared with about 20% amine-PEG-PE, about 20% methoxy-PEG-PE, and about 60% DSPC.

### Claim 11 (depends on 5)

The composition of claim 5, further comprising a coating, wherein the coating comprises a second polypeptide, wherein the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:10.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the first polypeptide comprises SEQ ID NO:2 and the second polypeptide comprises SEQ ID NO:7.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the first polypeptide consists essentially of SEQ ID NO:7 and the second polypeptide consists essentially of SEQ ID NO:2.